425: Strive & Semler Scientific Merger: Cautionary Filing

Strive, Inc. and Semler Scientific, Inc. filed a Form 425 regarding their proposed business combination, emphasizing forward-looking statements and associated risks.

Summary

• This Form 425 filing relates to the proposed business combination between Strive, Inc. and Semler Scientific, Inc.
• The communication was reposted on X.com by Ben Pham, Chief Financial Officer of Strive, Inc., on November 10, 2025.
• It includes a cautionary statement regarding forward-looking statements, highlighting inherent risks and uncertainties associated with the transaction.
• Investors are directed to read the Registration Statement on Form S-4, Information Statement/Proxy Statement/Prospectus, and other relevant SEC documents for important information about the proposed transaction.
• Strive and Semler Scientific, along with their respective directors, executive officers, and employees, may be deemed participants in the solicitation of proxies from Semler Scientific stockholders.
• This communication does not constitute an offer to sell or a solicitation of an offer to buy any securities or a solicitation of any vote of approval.

Sentiment

Score: 5

Explanation: The filing is a standard legal disclosure for a proposed merger, primarily focused on outlining forward-looking statements and a comprehensive list of risks. It is neutral in tone, as required for regulatory compliance, but the extensive risk factors lean slightly towards caution.

Positives

• The proposed business combination is expected to yield strategic and financial benefits for the combined company.
• Anticipated cost savings and strategic gains are expected to result from the successful integration of the combined businesses.

Risks

• The merger agreement could be terminated by either Strive or Semler Scientific due to unforeseen events, changes, or circumstances.
• The proposed transaction may not close when expected or at all if closing conditions are not met or satisfied on a timely basis.
• Legal proceedings may be instituted against Strive, Semler Scientific, or the combined company, impacting the transaction.
• Anticipated benefits, including cost savings and strategic gains, may not be realized as expected or at all.
• Changes in, or problems arising from, the implementation of Bitcoin treasury strategies and risks associated with Bitcoin and other digital assets could affect outcomes.
• General economic and market conditions, interest and exchange rates, monetary policy, laws, and regulations and their enforcement could negatively impact the combined company.
• The integration of the two companies may prove more difficult, time-consuming, or costly than initially expected.
• The proposed transaction may be more expensive or take longer to complete than anticipated due to unexpected factors or events.
• Management's attention may be diverted from ongoing business operations and opportunities during the transaction process.
• Strive's issuance of additional shares of its Class A common stock in connection with the proposed transaction will cause dilution for existing shareholders.
• Potential adverse reactions from customers or changes to business or employee relationships may arise from the announcement or completion of the proposed transaction.
• Changes in Strive's or Semler Scientific's share price before closing could occur.
• Other unknown or unpredictable factors could harm the results of Strive, Semler Scientific, or the combined company.

Future Outlook

The filing contains forward-looking statements regarding the outlook and expectations of Strive and Semler Scientific concerning the proposed transaction. These include anticipated strategic and financial benefits, the expected impact on the combined company's future financial performance, the timing of the closing, and the ability to successfully integrate the combined businesses. These statements are inherently subject to various risks and uncertainties.

Management Comments

• Ben Pham, Chief Financial Officer of Strive, Inc., reposted the communication on X.com.

Industry Context

This filing does not provide specific industry context beyond the general nature of a business combination in the financial/healthcare technology sector.

Legal Proceedings

• The outcome of any legal proceedings that may be instituted against Strive or Semler Scientific or the combined company is identified as a potential risk factor.

Related Party Transactions

• Information regarding Semler Scientific's transactions with related persons is detailed in its definitive proxy statement for the 2025 Annual Meeting of Stockholders.

Stakeholder Impact

• Potential adverse reactions from Strive's or Semler Scientific's customers could occur.
• Changes to business or employee relationships may result from the announcement or completion of the proposed transaction.
• Shareholders of Strive will experience dilution due to the issuance of additional Class A common stock in connection with the merger.

Next Steps

• A definitive Information Statement/Proxy Statement/Prospectus will be sent to the stockholders of Semler Scientific to seek their approval of the proposed transaction.
• Investors and stockholders are urged to read the Registration Statement and Information Statement/Proxy Statement/Prospectus when they become available.
• Strive and Semler Scientific may file other relevant documents concerning the proposed transaction with the SEC.

Key Dates

Keywords

Strive Inc, Semler Scientific Inc, Merger, Business Combination, SEC Filing, Form 425, Forward-Looking Statements, Risk Factors, Corporate Governance, Stock Issuance, Bitcoin Treasury Strategy